RxDoctor Payments Data

Jessica Bethell Barsocchi

Physician Assistant · Langhorne, PANPI 1073580452

Payments from drug & device makers

$3,471in general payments, 2019–2025

Across 190 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Johnson & Johnson$621
  • E.r. Squibb & Sons, L.L.C.$579
  • Merck$292
  • Novartis$182
  • Boehringer Ingelheim$164
  • plus $522 from 10 others

What the payments were for

  • Food & beverage$3,45199%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,471 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,972
Medicare patients
102
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban353$396,320
CamzyosMavacamten24$189,118
XareltoRivaroxaban147$178,002
EntrestoSacubitril/Valsartan108$151,132
Repatha SureclickEvolocumab99$110,810
FarxigaDapagliflozin Propanediol84$85,952
JardianceEmpagliflozin59$60,040
Carvedilol ErCarvedilol Phosphate17$10,892
Metoprolol Succinate476$7,329
Atorvastatin Calcium591$7,285
Ranolazine ErRanolazine48$6,522
Rosuvastatin Calcium358$5,454
Losartan Potassium251$3,122
Carvedilol311$3,051
Valsartan82$3,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$396,320353 claims
E.r. Squibb & Sons, L.L.C.Camzyos$579$189,11824 claims
Johnson & JohnsonXarelto$621$178,002147 claims
NovartisEntresto$182$151,132108 claims
AstraZenecaFarxiga$66$85,95284 claims
Boehringer IngelheimJardiance$164$60,04059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →